NA
SCLN

Navellier & Associates’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Navellier & Associates’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-26,032
Closed -$286K – 337
2017
Q2 		$286K Sell
26,032
-4,407
-14% -$44.1K 0.04% 248
2017
Q1 		$298K Buy
30,439
+2,614
+9% +$26.1K 0.04% 247
2016
Q4 		$301K Buy
27,825
+13,499
+94% +$135K 0.05% 229
2016
Q3 		$147K Buy
+14,326
New +$156K 0.02% 244

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Navellier & Associates's SCLN Position: Q3 2017 in Review

Navellier & Associates sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2017, closing a stake of 26,032 shares — an estimated $286K sold.

Navellier & Associates first reported a position in SCLN in Q3 2016 and held it in 4 quarters. The position peaked at $301K in Q4 2016. 129 funds tracked by Wall St. Rank hold SCLN as of Q3 2017.

  • Navellier & Associates reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • Navellier & Associates sold 26,032 Sciclone Pharmaceuticals Inc shares in Q3 2017, an estimated $286K.
  • Navellier & Associates first reported a position in Sciclone Pharmaceuticals Inc in Q3 2016 and held it in 4 quarters.
  • Navellier & Associates's Sciclone Pharmaceuticals Inc position peaked at $301K in Q4 2016.
  • 129 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2017.

Based on Navellier & Associates's 13F filing for Q3 2017, filed 14 Nov 2017.